Checkpoint inhibitor colitis: a new model of inflammatory bowel disease?

Current Opinion in Gastroenterology
Spyros I Siakavellas, Giorgos Bamias

Abstract

Immune checkpoint inhibitors are monoclonal antibodies against the inhibitory, co-stimulatory molecules CTLA-4 and PD-1/PD-L1. Their use in oncology has been associated with frequent and diverse immune-related adverse events. In the digestive tract, such toxicity presents primarily as colonic inflammation, resembling inflammatory bowel disease (IBD). This review presents recent developments regarding the characteristics of checkpoint inhibitor colitis (CIC) and its relation to IBD. Several reports from patient cohorts with CIC have outlined its similarities and differences with IBD. Clinically and endoscopically, there is high overlap, including the negative prognostic significance of deep ulceration. Histologically, CIC may present as either acute colitis or demonstrate features of chronic damage, including IBD-like and lymphocytic colitis-like phenotypes. CIC immunopathogenesis appears to be associated with a predominance of mucosal Th1/Th17 effector responses, and may also be influenced by input from the gut microflora. Finally, current treatment of CIC is based on steroids and infliximab, although other biologics such as vedolizumab may also be effective. CIC represents a distinct form of colitis with characteristics remini...Continue Reading

References

Jan 10, 2002·Gastroenterology·David M SpencerAlan D Levine
Oct 22, 2003·The Journal of Immunology : Official Journal of the American Association of Immunologists·Giorgos BamiasFabio Cominelli
May 16, 2006·Proceedings of the National Academy of Sciences of the United States of America·Giorgos BamiasFabio Cominelli
Apr 20, 2007·The Journal of Immunology : Official Journal of the American Association of Immunologists·Stefan Fichtner-FeiglWarren Strober
Mar 23, 2012·Nature Reviews. Cancer·Drew M Pardoll
Sep 2, 2015·The Journal of Clinical Investigation·Elizabeth Buchbinder, F Stephen Hodi
Sep 17, 2015·Current Opinion in Gastroenterology·Giorgos Bamias, Fabio Cominelli
May 27, 2016·Scientific Reports·Jack RobertsonJonathan J Powell
Aug 20, 2016·BMJ Case Reports·Amy Hsin-Chieh HsiehJane M Andrews
Sep 24, 2016·Cellular Immunology·Mohammad Reza ZamaniNima Rezaei
Oct 1, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A M MenziesG V Long
Feb 17, 2017·Cancer Immunology, Immunotherapy : CII·Viktoria BergqvistJan Marsal
Feb 20, 2017·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Ralf GutzmerUNKNOWN German Dermatooncology Group (DeCOG)
Mar 16, 2017·The American Journal of Surgical Pathology·Jonathan H ChenRicard Masia
Apr 4, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·N ChaputF Carbonnel
Apr 5, 2017·World Journal of Gastroenterology : WJG·Animesh JainMark G Lazarev
May 18, 2017·Pediatric Allergy and Immunology : Official Publication of the European Society of Pediatric Allergy and Immunology·Daniel TegtmeyerChristian Klemann
May 27, 2017·Cancer Investigation·Giorgos BamiasHelen Gogas
Sep 9, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J B A G HaanenUNKNOWN ESMO Guidelines Committee
Oct 27, 2017·BMB Reports·Seong Jeong ParkYunji Park
Dec 20, 2017·Proceedings of the National Academy of Sciences of the United States of America·Feng WangMark M Davis
Apr 11, 2018·Comptes rendus biologies·Anne-Gaëlle GoubetLaurence Zitvogel
Apr 29, 2018·Journal of Clinical Pathology·Dipti M Karamchandani, Runjan Chetty
May 3, 2018·Inflammatory Bowel Diseases·Yinghong WangAdi Diab
Jun 11, 2018·Current Opinion in Chemical Biology·Anthony LeeTien Hoang
Jul 1, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J B A G HaanenUNKNOWN ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org

❮ Previous
Next ❯

Citations

Dec 12, 2019·Frontiers in Oncology·Manqing Wu, Jun Shen
May 10, 2020·Nature Reviews. Disease Primers·Manuel Ramos-CasalsMaria E Suárez-Almazor
Sep 20, 2020·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Giorgos Bamias, Fabio Cominelli
Feb 11, 2021·The New England Journal of Medicine·Anusha S ThomasYinghong Wang
Dec 5, 2020·International Journal of Molecular Sciences·Marina ChulkinaIrina V Pinchuk
Jan 8, 2021·Cancer Immunology, Immunotherapy : CII·Noha Abdel-WahabMaria E Suarez-Almazor
Feb 28, 2021·Abdominal Radiology·Mariko KurokawaYasunobu Takaki
Mar 23, 2021·Expert Opinion on Drug Safety·Remo PotoGilda Varricchi
Aug 31, 2021·World Journal of Gastrointestinal Oncology·Alexa R WeingardenJohn Gubatan
Aug 5, 2021·Journal of Crohn's & Colitis·Roger FeakinsMonika Tripathi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

© 2022 Meta ULC. All rights reserved